ZA200705540B - Compositions comprising PDE4 modulators and their use for the treatment or prevention of airway inflammation - Google Patents

Compositions comprising PDE4 modulators and their use for the treatment or prevention of airway inflammation

Info

Publication number
ZA200705540B
ZA200705540B ZA200705540A ZA200705540A ZA200705540B ZA 200705540 B ZA200705540 B ZA 200705540B ZA 200705540 A ZA200705540 A ZA 200705540A ZA 200705540 A ZA200705540 A ZA 200705540A ZA 200705540 B ZA200705540 B ZA 200705540B
Authority
ZA
South Africa
Prior art keywords
prevention
compositions
treatment
airway inflammation
pde4 modulators
Prior art date
Application number
ZA200705540A
Other languages
English (en)
Inventor
Jerome B Zeldis
Patricia E W Rohane
Peter H Schafer
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of ZA200705540B publication Critical patent/ZA200705540B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
ZA200705540A 2004-12-13 2005-12-12 Compositions comprising PDE4 modulators and their use for the treatment or prevention of airway inflammation ZA200705540B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US63498204P 2004-12-13 2004-12-13

Publications (1)

Publication Number Publication Date
ZA200705540B true ZA200705540B (en) 2009-01-28

Family

ID=36121316

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200705540A ZA200705540B (en) 2004-12-13 2005-12-12 Compositions comprising PDE4 modulators and their use for the treatment or prevention of airway inflammation

Country Status (13)

Country Link
US (1) US20060148882A1 (https=)
EP (1) EP1838294A1 (https=)
JP (1) JP2008523102A (https=)
KR (1) KR20070092276A (https=)
CN (1) CN101111235A (https=)
AR (1) AR052047A1 (https=)
AU (1) AU2005316593A1 (https=)
BR (1) BRPI0519030A2 (https=)
CA (1) CA2590903A1 (https=)
IL (1) IL183858A0 (https=)
MX (1) MX2007006992A (https=)
WO (1) WO2006065814A1 (https=)
ZA (1) ZA200705540B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050100529A1 (en) * 2003-11-06 2005-05-12 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
US20050239867A1 (en) * 2004-04-23 2005-10-27 Zeldis Jerome B Methods of using and compositions comprising PDE4 modulators for the treatment and management of pulmonary hypertension
WO2007045980A1 (en) * 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type iv inhibitors
PE20120580A1 (es) * 2009-02-10 2012-05-23 Celgene Corp Metodos para utilizar y composiciones que comprenden moduladores pde4 para tratamiento, prevencion y control de tuberculosis
BRPI1012770B8 (pt) 2009-05-14 2021-05-25 Tianjin Hemay Bio Tech Co Ltd derivados de tiofeno
MX341050B (es) * 2010-04-07 2016-08-05 Celgene Corp * Metodos para tratar infeccion viral respiratoria.
WO2012083017A2 (en) 2010-12-16 2012-06-21 Celgene Corporation Controlled release oral dosage forms of poorly soluble drugs and uses thereof
WO2012096859A2 (en) * 2011-01-10 2012-07-19 Celgene Corporation Oral dosage forms of cyclopropanecarboxylic acid {2-[(1s)-1-(3-ethoxy-4-methoxy-phenyl]-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1h-isoindol-4-yl}-amide
MX347928B (es) 2011-01-10 2017-05-19 Celgene Corp Derivados de fenetilsulfona isoindolina y su uso.
WO2012121988A2 (en) 2011-03-07 2012-09-13 Celgene Corporation Methods for treating diseases using isoindoline compounds
CN103635188B (zh) 2011-04-28 2017-03-22 细胞基因公司 使用pde4抑制剂用于治疗和控制自身免疫性疾病和炎性疾病的方法和组合物
CN105050624A (zh) 2013-03-14 2015-11-11 细胞基因公司 利用阿普斯特来治疗银屑病关节炎的方法
WO2015112568A1 (en) * 2014-01-24 2015-07-30 Celgene Corporation Methods for the treatment of obesity using apremilast
US10092541B2 (en) 2014-08-15 2018-10-09 Celgene Corporation Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast
WO2017030892A1 (en) 2015-08-14 2017-02-23 Reaction Biology Corp. Histone deacetylase inhibitors and methods for use thereof
RU2743126C9 (ru) * 2016-08-22 2021-04-27 Шицзячжуан Сагесити Нью Драг Дивелопмент Ко., Лтд. Ингибитор pde4
KR102318401B1 (ko) * 2017-02-28 2021-10-29 강푸 바이오파마슈티칼즈 리미티드 신규한 이소인돌린 유도체, 이의 약학 조성물 및 용도
AU2018234059A1 (en) * 2017-03-16 2019-10-31 Takeda Gmbh Treatment of idiopathic pulmonary fibrosis
GB202306663D0 (en) 2023-05-05 2023-06-21 Union Therapeutics As Combination therapy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020358A (en) * 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels
US6667316B1 (en) * 1999-11-12 2003-12-23 Celgene Corporation Pharmaceutically active isoindoline derivatives
US6699899B1 (en) * 1999-12-21 2004-03-02 Celgene Corporation Substituted acylhydroxamic acids and method of reducing TNFα levels
US6962940B2 (en) * 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7276529B2 (en) * 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
EP1567154A4 (en) * 2002-11-06 2006-05-31 Celgene Corp METHODS AND COMPOSITIONS USING CYTOKINE SELECTIVE INHIBITION DRUGS FOR TREATING AND CONTROLLING CANCERS AND OTHER DISEASES
JP2006510617A (ja) * 2002-11-18 2006-03-30 セルジーン・コーポレーション （＋）−３−（３，４−ジメトキシ−フェニル）−３−（１−オキソ−１，３−ジヒドロ−イソインドール−２−イル）−プロピオンアミドの使用方法およびそれを含む組成物
DE60330187D1 (de) * 2002-12-30 2009-12-31 Celgene Corp Fluoralkoxy-substituierte 1, 3-dihydro-isoindolyl-verbindungen und ihre pharmazeutischen verwendungen
US20050239867A1 (en) * 2004-04-23 2005-10-27 Zeldis Jerome B Methods of using and compositions comprising PDE4 modulators for the treatment and management of pulmonary hypertension
AU2004319815A1 (en) * 2004-05-05 2005-12-01 Celgene Corporation Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
US7244759B2 (en) * 2004-07-28 2007-07-17 Celgene Corporation Isoindoline compounds and methods of making and using the same

Also Published As

Publication number Publication date
US20060148882A1 (en) 2006-07-06
CN101111235A (zh) 2008-01-23
EP1838294A1 (en) 2007-10-03
KR20070092276A (ko) 2007-09-12
BRPI0519030A2 (pt) 2008-12-23
IL183858A0 (en) 2007-10-31
MX2007006992A (es) 2007-08-03
JP2008523102A (ja) 2008-07-03
WO2006065814A1 (en) 2006-06-22
AU2005316593A1 (en) 2006-06-22
AR052047A1 (es) 2007-02-28
CA2590903A1 (en) 2006-06-22

Similar Documents

Publication Publication Date Title
IL183858A0 (en) Compositions comprising pde4 modulators and their use for the treatment or prevention of airway inflammation
IL181896A0 (en) Methods and compositions for the treatment of hyperlipidemia
ZA200607433B (en) Methods and compositions for the treatment of gastroin-testinal disorders
ZA200704677B (en) Compositions and methods for the treatment of autism
EP2318033B8 (en) Compositions for the treatment of pain and/or inflammation
IL182574A0 (en) Gpr41 and modulators thereof for the treatment of insulin-related disorders
PT1594867E (pt) Fenilacetamidas e sua utilização como moduladores de glucocinase
IL178860A (en) Certain chemical entities, preparations and processes
ZA200702007B (en) Herbal compositions for the prevention or treatment of urinary incontinence and overactive bladder
IL187565A0 (en) Compositions and methods for the treatment or prevention of chemoresistant neoplasia
AU2003291480A8 (en) Composition for the prevention and treatment of inflammation of the ear
EP2079526A4 (en) COMPOSITIONS AND ITS USES IN THE TREATMENT OF WOUNDS
IL178788A0 (en) Methods of using and compositions comprising pde4 modulators for the treatment and management of pulmonary hypertension
GB0610350D0 (en) prevention and/or treatment of neuodegenerative disorders
ZA200703087B (en) Methods and compositions for the treatment of hyperlipidemia
EP1814567A4 (en) USE OF MODULATORS OF EPHA2 AND EPHRINA1 FOR TREATING AND PREVENTING INFECTIONS
IL198721A0 (en) Acat inhibitors and their use in the prevention or treatment of fibrosis
IL197766A0 (en) Use of oritavancin for the prevention and treatment of anthrax
ZA200800981B (en) Use of SDF-1 for the treatment and/or prevention of neurological diseases
EP1812797A4 (en) COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING HYPERPROLIFERATIVE DISEASES
GB0425633D0 (en) Topical formulations for use in the treatment or prevention of dermatological conditions
EP1819724A4 (en) BETA 2-GLYCOPROTEIN I COMPOSITIONS FOR THE PREVENTION AND / OR TREATMENT OF VASCULAR DISEASES
IL180526A0 (en) Composition for the prevention and treatment of allergic inflammatory disease
IL177751A0 (en) Pharmaceutical composition of (+)-erythro-mefloquine and its use
HK1099682A (zh) 炎症治療用組合物及方法